Dr Nicola Annels

Research Fellow

Qualifications: BSc PhD

Email:
Phone: Work: 01483 68 8562
Room no: 09 PGM 02

Office hours

9am to 5pm Monday-Friday

Further information

Biography

1992-1995     B.Sc. Upper Second Class (Hons), Biological Sciences, University of Southampton, UK

 

1995-1999     PhD., University of Birmingham, Immunology

   Under the supervision of Prof. Alan Rickinson my research focused on CD8+ T cell responses to     Epstein-Barr Virus (EBV) antigens.

 

1999-2000     Postdoctoral researcher, CRC Institute for Cancer Studies, University of Birmingham,        Edgbaston, Birmingham, UK

                        The research followed on from my PhD using Epstein Barr virus as a model system in which to         investigate the establishment of immunological memory

 

2000-2007     Postdoctoral Fellow, Leiden University Medical Center, Paediatrics, Leiden, The Netherlands

                        My project involved the identification of the homing receptor profiles and functional characterization of T cells involved in the pathogenesis and regulation of acute GvHD. In addition, I also collaborated with Prof. R.Maarten Egeler on a project trying to elucidate the pathophysiology and etiology of Langerhans cell histiocytosis.

 

2007-to date Senior Postdoctoral Fellow, Postgraduate Medical School, University of Surrey, Guildford, UK

                        I currently oversee the immunological research in the Oncology group headed by Prof Hardev Pandha. Our research projects focus on developing new immunotherapeutic strategies to treat cancer patients. This involves both the identification of novel immunotherapeutic target antigens as well as developing new strategies to abrogate the immunosuppressive mechanisms active in cancer.

 

Research Interests

Main interests are in tumour immunology, immunotherapy and regulatory T cells

 

Publications

Journal articles

  • Annels NE, Simpson GR, Denyer M, McGrath SE, Falgari G, Killick E, Eeles R, Stebbing J, Pchejetski D, Cutress R, Murray N, Michael A, Pandha H. (2014) 'Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer.'. Clin Exp Immunol, England: 177 (2), pp. 428-438.

    Abstract

    We reported the expression of the homeodomain-containing transcription factor Engrailed-2 (EN2) in prostate cancer and showed that the presence of EN2 protein in the urine was highly predictive of prostate cancer. This study aimed to determine whether patients with prostate cancer have EN2 autoantibodies, what the prevalence of these antibodies is and whether they are associated with disease stage. The spontaneous immunoglobulin (Ig)G immune response against EN2 and for comparison the tumour antigen New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1), were tested by enzyme-linked immunosorbent assay (ELISA) in three different cohorts of prostate cancer patients as well as a group of men genetically predisposed to prostate cancer. Thirty-two of 353 (9·1%) of the SUN cohort representing all stages of prostate cancer demonstrated EN2 IgG responses, 12 of 107 patients (11·2%) in the advanced prostate cancer patients showed responses, while only four of 121 patients (3·3%) with castrate-resistant prostate cancer showed EN2 autoantibodies. No significant responses were found in the predisposed group. Anti-EN2 IgG responses were significantly higher in patients with prostate cancer compared to healthy control males and similarly prevalent to anti-NY-ESO-1 responses. While EN2 autoantibodies are not a useful diagnostic or monitoring tool, EN2 immunogenicity provides the rationale to pursue studies using EN2 as an immunotherapeutic target.

  • Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, Valle J, Smith D, Wadsley J, Cunningham D, Pandha H, Neoptolemos JP, Middleton G. (2013) 'The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.'. Cancer Immunol Immunother,

    Abstract

    In pre-clinical models, the only two chemotherapy drugs which have been demonstrated to directly reduce the number of myeloid-derived suppressor cells (MDSCs) are gemcitabine and 5-fluorouracil. Here we analyze the dynamics of MDSCs, phenotyped as Lin-DR-CD11b+, in patients with advanced pancreatic cancer receiving the combination of gemcitabine and capecitabine, a 5-FU pro-drug. We found no evidence that gemcitabine and capecitabine directly reduce MDSC% in patients. Gemcitabine and capecitabine reduced MDSCs in 42 % of patients (n = 19) and MDSC% fell in only 3/9 patients with above-median baseline MDSCs. In 5/8 patients with minimal tumour volume change on treatment, the MDSC% went up: increases in MDSC% in these patients appeared to correlate with sustained cancer-related inflammatory cytokine upregulation. In a separate cohort of 21 patients treated with gemcitabine and capecitabine together with concurrently administered GV1001 vaccine with adjuvant GM-CSF, the MDSC% fell in 18/21 patients and there was a significant difference in the trajectory of MDSCs between those receiving GV1001 and GM-CSF in combination with chemotherapy and those receiving chemotherapy alone. Thus, there was no evidence that the addition of low-dose adjuvant GM-CSF increased Lin-DR-CD11b+ MDSC in patients receiving combination chemoimmunotherapy. 9/21 patients developed an immune response to GV1001 and the MDSCs fell in 8 of these 9 patients, 6 of whom had above-median pre-vaccination MDSC levels. A high pre-vaccination MDSC% does not preclude the development of immunity to a tumour-associated antigen.

  • Michael A, Relph K, Annels N, Pandha H. (2013) 'Prostate cancer vaccines.'. Expert Rev Vaccines, England: 12 (3), pp. 253-262.

    Abstract

    In 2010, the US FDA approved the first therapeutic cancer vaccine for the treatment of castration refractory prostate cancer - sipuleucel-T. Prostate cancer is an ideal model for cancer vaccine development based on the ready demonstration of humoral and cellular immunity to a range of cancer antigens as well as often slow progression which means that patients who are otherwise well may have a radiologically evaluable minor progression, after conventional treatment and can undergo vaccine therapy over sufficient periods of time, so as to allow the generation of a robust antitumor response. The association of prostate cancer with one of the few serum cancer biomarkers in general use has also allowed assessment of response and risk stratification of patients. In this review, we will examine key aspects of the evolution of prostate cancer vaccines, which provides an accurate prototype for other cancers, and the challenges we face.

  • Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, Peschard P, Price T, Coffin RS, Mostafid H, Melcher AA, Harrington KJ, Pandha HS. (2012) 'Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer'. BRITISH JOURNAL OF CANCER, 106 (3), pp. 496-507.
  • Middleton GW, Annels NE, Pandha HS. (2012) 'Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?'. Cancer Immunol Immunother, Germany: 61 (1), pp. 1-7.

    Abstract

    From a therapeutic perspective, the bourgeoning literature on Th17 cells should allow us to decide whether to rationally pursue the manipulation of Th17 cells in cancer. The purpose of this review is to attempt a synthesis of a number of contradictory conclusions as to the role that these cells are playing in the process of tumourigenesis in order to provide guidance as to whether our current understanding is sufficient to safely pursue Th17-targeted therapy in cancer at this time. Th17 cells are a highly plastic population and the cytokine drivers for Th17 cell generation and skewing will vary between various cancers and importantly between different sites of tumour involvement in any individual patient. The net impact of the pro-angiogenic IL-17 produced not only by Th17 cells but by other cells particularly macrophages and the anti-tumour effects of Th1/Th17 cells will in turn be determined by the complex interplay of diverse chemokines and cytokines in any tumour microenvironment. Th17 cells that fail to home to tumours may be immunosuppressive. The complexity of IL-17 and Th17 dynamics makes easy prediction of the effects of either enhancing or suppressing Th17 cell differentiation in cancer problematic.

  • Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. (2011) 'Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.'. Cancer Immunol Immunother,

    Abstract

    We undertook a comprehensive analysis of circulating myeloid-derived suppressor cells (MDSCs) and T regulatory cells (Tregs) in pancreatic, esophageal and gastric cancer patients and investigated whether MDSCs are an independent prognostic factor for survival. We evaluated a series of plasma cytokines and in particular re-evaluated the Th2 cytokine interleukin-13 (IL-13). Peripheral blood was collected from 131 cancer patients (46 pancreatic, 60 esophageal and 25 gastric) and 54 healthy controls. PBMC were harvested with subsequent flow cytometric analysis of MDSC (HLADR(-) Lin1(low/-) CD33(+) CD11b(+)) and Treg (CD4(+) CD25(+) CD127(low/-) FoxP3(+)) percentages. Plasma IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, IL-17, G-CSF, IFN-γ, TNF-α and VEGF levels were analyzed by the Bio-Plex cytokine assay. Plasma arginase I levels were analyzed by ELISA. MDSCs and Tregs were statistically significantly elevated in pancreatic, esophageal and gastric cancer compared with controls, and MDSC numbers correlated with Treg levels. Increasing MDSC percentage was associated with increased risk of death, and in a multivariate analysis, MDSC level was an independent prognostic factor for survival. A unit increase in MDSC percentage was associated with a 22% increased risk of death (hazard ratio 1.22, 95% confidence interval 1.06-1.41). Arginase I levels were also statistically significantly elevated in upper gastrointestinal cancer patients compared with controls. There was Th2 skewing for cytokine production in all three diseases, and importantly there were significant elevations of the pivotal Th2 cytokine interleukin-13, an increase that correlated with MDSC levels.

  • Gabitass RF, Annels NE, Crawshaw J, Pandha HS, Middleton GW. (2011) 'Use of gemcitabine- (Gem) and fluropyrimidine (FP)-based chemotherapy to reduce myeloid-derived suppressor cells (MDSCs) in pancreatic (PC) and esophagogastric cancer (EGC).'. JOURNAL OF CLINICAL ONCOLOGY, 29 (15)
  • Michael A, Riley C, Bokaee S, Denyer M, Pandha HS, Annels NE. (2011) 'EN2: A candidate antigen for the development of targeted therapies in ovarian cancer.'. JOURNAL OF CLINICAL ONCOLOGY, 29 (15)
  • Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, Whitaker HC, Neal DE, Ismail M, Whitaker H, Annels N, Michael A, Pandha H. (2011) 'Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer.'. Clin Cancer Res, United States: 17 (5), pp. 1090-1098.

    Abstract

    Prostate cancer (PC) is the second most common cause of cancer related death in men. A number of key limitations with prostate specific antigen (PSA), currently the standard detection test, has justified evaluation of new biomarkers. We have assessed the diagnostic potential of Engrailed-2 (EN2) protein, a homeodomain-containing transcription factor expressed in PC cell lines and secreted into the urine by PC in men.

  • Gabitass RF, Annels NE, Pandha HA, Middleton GW, Stocken DD. (2011) 'Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13'. Cancer Immunology, Immunotherapy, 60 (10), pp. 1419-1430.

    Abstract

    We undertook a comprehensive analysis of circulating myeloid-derived suppressor cells (MDSCs) and T regulatory cells (Tregs) in pancreatic, esophageal and gastric cancer patients and investigated whether MDSCs are an independent prognostic factor for survival. We evaluated a series of plasma cytokines and in particular re-evaluated the Th2 cytokine interleukin-13 (IL-13). Peripheral blood was collected from 131 cancer patients (46 pancreatic, 60 esophageal and 25 gastric) and 54 healthy controls. PBMC were harvested with subsequent flow cytometric analysis of MDSC (HLADR Lin1 CD33 CD11b ) and Treg (CD4 CD25 CD127 FoxP3 ) percentages. Plasma IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, IL-17, G-CSF, IFN-γ, TNF-α and VEGF levels were analyzed by the Bio-Plex cytokine assay. Plasma arginase I levels were analyzed by ELISA. MDSCs and Tregs were statistically significantly elevated in pancreatic, esophageal and gastric cancer compared with controls, and MDSC numbers correlated with Treg levels. Increasing MDSC percentage was associated with increased risk of death, and in a multivariate analysis, MDSC level was an independent prognostic factor for survival. A unit increase in MDSC percentage was associated with a 22% increased risk of death (hazard ratio 1.22, 95% confidence interval 1.06-1.41). Arginase I levels were also statistically significantly elevated in upper gastrointestinal cancer patients compared with controls. There was Th2 skewing for cytokine production in all three diseases, and importantly there were significant elevations of the pivotal Th2 cytokine interleukin-13, an increase that correlated with MDSC levels. © 2011 The Author(s).

  • Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R, Harrington KJ, Pandha HS. (2010) 'The Effect of Cell Cycle Synchronization on Tumor Sensitivity to Reovirus Oncolysis'. MOLECULAR THERAPY, 18 (12), pp. 2085-2093.
  • Faaij CMJM, Willemze AJ, Revesz T, Balzarolo M, Tensen CP, Hoogeboom M, Vermeer MH, van Wering E, Zwaan CM, Kaspers GJL, Story C, van Halteren AGS, Vossen JM, Egeler RM, van Tol MJD, Annels NE. (2010) 'Chemokine/Chemokine Receptor Interactions in Extramedullary Leukaemia of the Skin in Childhood AML: Differential Roles for CCR2, CCR5, CXCR4 and CXCR7'. PEDIATRIC BLOOD & CANCER, 55 (2), pp. 344-348.
  • Faaij CM, Annels NE, Ruigrok G, van der Burg M, Ball LM, Bredius RG, van Tol MJ, Lankester AC. (2010) 'Decrease of Skin Infiltrating and Circulating CCR10+T Cells Coincides with Clinical Improvement after Topical Tacrolimus in Omenn Syndrome'. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 130 (1), pp. 308-311.
  • Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, Azocar O, Flacher M, Djebali S, Tebib J, Brytting M, Egeler RM, Rabourdin-Combe C, Henter JI, Arico M, Delprat C. (2009) 'LANGERHANS CELL HISTIOCYTOSIS REVEALS A NEW IL-17A-DEPENDENT PATHWAY OF DENDRITIC CELL FUSION'. PEDIATR BLOOD CANCER, 53 (4), pp. 686-686.
  • da Costa CET, Szuhai K, van Eijk R, Hoogeboom M, Sciot R, Mertens F, Bjorgvinsdottir H, Debiec-Rychter M, de Krijger RR, Hogendoorn PCW, Egeler RM, Annels NE. (2009) 'No Genomic Aberrations in Langerhans Cell Histiocytosis as Assessed by Diverse Molecular Technologies'. GENES CHROMOSOMES & CANCER, 48 (3), pp. 239-249.
  • Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, Azocar O, Flacher M, Djebali S, Tebib J, Brytting M, Egeler RM, Rabourdin-Combe C, Henter J-I, Arico M, Delprat C. (2008) 'Langerhans cell histiocytosis reveals a new IL-17A dependent pathway of dendritic cell fusion'. NATURE MEDICINE, 14 (1), pp. 81-87.
  • Costa C, Annels N, Hoogeboom M, Szuhai K, Hogendoorn P, Egeler M. (2007) 'Investigation of potential chromosomal abnormalities in the lesional cells of Langerhans cell histiocytosis'. PEDIATRIC BLOOD & CANCER, 48 (7), pp. 753-754.
  • da Costa CET, Egeler RM, Hoogeboorn M, Szuhai K, Forsyth RG, Niesters M, de Krijger RR, Tazi A, Hogendoorn PCW, Annels NE. (2007) 'Differences in telomerase expression by the CD1a(+) cells in Langerhans cell histiocytosis reflect the diverse clinical presentation of the disease'. JOURNAL OF PATHOLOGY, 212 (2), pp. 188-197.
  • Annels NE, Kalpoe JS, Bredius RGM, Claas EC, Kroes ACM, Hislop AD, van Baarle D, Egeler RM, van Tol MJD, Lankester AC. (2006) 'Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution'. CLINICAL INFECTIOUS DISEASES, 42 (12), pp. 1743-1748.
  • Faaij CMJM, Lankester AC, Spierings E, Hoogeboom M, Bowman EP, Bierings M, Revesz T, Egeler RM, van Tol MJD, Annels NE. (2006) 'A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4(+) T cells to skin in human graft-versus-host disease'. BRITISH JOURNAL OF HAEMATOLOGY, 133 (5), pp. 538-549.
  • da Costa CET, Annels NE, Faaij CMJM, Forsyth RG, Hogendoorn PCW, Egeler RM. (2005) 'Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis'. JOURNAL OF EXPERIMENTAL MEDICINE, 201 (5), pp. 687-693.
  • Costa C, Annels NE, Faaij C, Hoogendorn P, Egeler RM. (2004) 'The role of multinucleated giant cells in Langerhans cell histiocytosis'. PEDIATRIC BLOOD & CANCER, 43 (2), pp. 199-199.
  • Egeler RM, Annels NE, Hogendoorn PCW. (2004) 'Commentary - Langerhans cell histiocytosis: A pathologic combination of oncogenesis and immune dysregulation'. PEDIATRIC BLOOD & CANCER, 42 (5), pp. 401-403.
  • Annels NE, Willemze AJ, van der Velden VHJ, Faaij CMJM, van Wering E, Sie-Go DMDS, Egeler RM, van Tol MJD, Revesz T. (2004) 'Possible link between unique chemokine and homing receptor expression at diagnosis and relapse location in a patient with childhood T-ALL'. BLOOD, 103 (7), pp. 2806-2808.
  • Egeler RM, Laman JD, Leenen PJM, Annels NE, Hogendoorn PCW. (2003) 'Response to Fadeel and Henter: Langerhans cell histiocytosis: a combination of carcinogenesis and inflammation'. TRENDS IN IMMUNOLOGY, 24 (8), pp. 410-411.
  • Annels NE, da Costa CET, Prins FA, Willemze A, Hogendoorn PCW, Egeler RM. (2003) 'Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis'. JOURNAL OF EXPERIMENTAL MEDICINE, 197 (10), pp. 1385-1390.
  • Laman JD, Leenen PJM, Annels NE, Hogendoorn PCW, Egeler RM. (2003) 'Langerhans-cell histiocytosis 'insight into DC biology''. TRENDS IN IMMUNOLOGY, 24 (4), pp. 190-196.
  • Dunne PJ, Faint JM, Gudgeon NH, Fletcher JM, Plunkett FJ, Scares MVD, Hislop AD, Annels NE, Rickinson AB, Salmon M, Akbar AN. (2002) 'Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential'. BLOOD, 100 (3), pp. 933-940.
  • Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. (2002) 'Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection'. JOURNAL OF EXPERIMENTAL MEDICINE, 195 (7), pp. 893-905.
  • Faint JM, Annels NE, Curnow SJ, Shields P, Pilling D, Hislop AD, Wu LJ, Akbar AN, Buckley CD, Moss PAH, Adams DH, Rickinson AB, Salmon M. (2001) 'Memory T cells constitute a subset of the human CD8(+)CD45RA(+) pool with distinct phenotypic and migratory characteristics'. JOURNAL OF IMMUNOLOGY, 167 (1), pp. 212-220.
  • Annels NE, Callan MFC, Tan L, Rickinson AB. (2000) 'Changing patterns of dominant TCR usage with maturation of an EBV-specific cytotoxic T cell response'. JOURNAL OF IMMUNOLOGY, 165 (9), pp. 4831-4841.
  • Tan LC, Gudgeon N, Annels NE, Hansasuta P, O'Callaghan CA, Rowland-Jones S, McMichael AJ, Rickinson AB, Callan MFC. (1999) 'A re-evaluation of the frequency of CD8(+) T cells specific for EBV in healthy virus carriers'. JOURNAL OF IMMUNOLOGY, 162 (3), pp. 1827-1835.
  • Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. (1997) 'Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response'. JOURNAL OF EXPERIMENTAL MEDICINE, 185 (9), pp. 1605-1617.
  • Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB. (1996) 'Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory'. JOURNAL OF EXPERIMENTAL MEDICINE, 184 (5), pp. 1801-1813.

Conference papers

  • Annels NE, Simpson GR, Bokaee S, Riley C, Denyer M, Pandha H, Morgan R. (2012) 'Modulation of Regulatory T Cells by Targeting The NFAT-FOXP3 Protein: Protein Interaction'. LIPPINCOTT WILLIAMS & WILKINS JOURNAL OF IMMUNOTHERAPY, North Bethesda, MD: 27th Annual Scientific Meeting of the Society-for-Immunotherapy-of-Cancer (SITC) 35 (9), pp. 775-775.
  • Killick E, Morgan R, Launchbury F, Annels NE, Bancroft E, Page E, Castro E, Kote-Jarai Z, Eeles RA, Pandha HS. (2012) 'Detecting prostate cancer in BRCA1 and BRCA2 mutation carriers: A role for EN2?'. AMER SOC CLINICAL ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) 30 (15)
  • McGrath S, Annels NE, Madhuri TK, Haagsma B, Larbi ED, Pandha HS, Michael A. (2012) 'Engrailed protein: A cancer-specific marker in epithelial ovarian cancer'. AMER SOC CLINICAL ONCOLOGY JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) 30 (15)
  • Michael A, Riley, C, Bokaee S, Denyer M, Pandha H, Annels N. (2011) 'EN2: A candidate antigen for the development of targeted therapies in ovarian cancer.'. JCO, Chicago: ASCO (J Clin Oncol 29: 2011 (suppl; abstr e15528))

    Abstract

    Background: Ovarian cancer remains the most lethal gynaecologic tumour in the Western world. Stimulation of the immune system to consolidate response to chemotherapy can potentially be beneficial however so far none of the vaccination strategies have offered survival advantage. Thus identifying and targeting clinically relevant antigens for immunotherapy continues to be an important research strategy. We have evaluated Engrailed-2 (EN2) as a potential target for vaccine strategy. EN2 is a homeodomain-containing transcription factor with a multifunctional role in neural development. There is evidence that over-expression of EN2 protein maybe linked to tumour development. Methods: Ovarian cancer cell lines were analysed by FACS for EN2 cell surface expression. EN2 expression in ovarian cancer tissue arrays were done by immunohistochemistry. A serum analysis (ELISA) was done to evaluate the presence of antibodies to EN2 in ovarian cancer patients and age-matched controls. A set of potentially immunogenic HLA-A2 restricted epitopes from the EN2 protein was identified using a computer algorithm SYFPEITHI. These peptides have been tested on HLA-A2 positive ovarian cancer patients’ PBMC using an in vitro culture method. The specificity of these T cell lines was analysed against T2 target cells loaded with or without EN2 peptides Results: Cell surface expression of EN2 was observed in ovarian cancer cell lines OVCAR3, OV90, CaOV-3, ES-2 and SKOV-3 of which ES-2 and SKOV3 showed strong expression. EN2 was also present in approximately 80% of ovarian cancer tissues whereas EN-2 expression was very low (<10%) or absent in normal tissues. Out of the 67 ovarian cancer patients 20.9% (14/67) had antibodies against EN2 compared to 2.4% (1/42) of age-matched female controls. 4 of the identified EN2 epitopes were able to generate peptide specific cytotoxic T lymphocytes in the ovarian cancer patients tested. Conclusions: The over-expression and immunogenicity of EN2 in ovarian cancer makes it a credible antigen to exploit as a novel target for ovarian cancer immunotherapy. ž

  • Ismail MI, Bokaee S, Annels N, Davies J, Pandha H. (2011) 'Predominance of CD8 T cell infiltration coincides with reciprocal reduction in regulatory T cells following prostate cryotherapy'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Coll Surgery, Dublin, IRELAND: Annual Meeting of the Society-of-Academic-and-Research-Surgery 98, pp. 48-48.
  • Simpson GR, Horvath A, Harrington K, Coffin RS, Pandha H. (2008) 'Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer'. PERGAMON-ELSEVIER SCIENCE LTD EJC SUPPLEMENTS, Geneva, SWITZERLAND: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 6 (12), pp. 97-98.
  • Costa C, Egeler M, Forsyth R, Szuhai K, Niesters M, de Krijger R, Tati A, Hogendoorn P, Annels N. (2007) 'Differences in telomerase expression by the CD1 a+ cells in langerhans cell histiocytosis reflects the diverse clinical presentation of the disease'. ACADEMIC PRESS INC ELSEVIER SCIENCE CLINICAL IMMUNOLOGY, San Diego, CA: 7th Annual Meeting of the Federation-of-Clinical-Immunology-Societies 123, pp. S50-S50.
  • Faaij C, Annels N, van den Burg M, Langerak A, Ruigrok G, Bowman E, van Tol M, Lankester A. (2006) 'Identification of a clonal population of CCR10+ skin-homing T-cells in an Omenn Syndrome patient.'. ACADEMIC PRESS INC ELSEVIER SCIENCE CLINICAL IMMUNOLOGY, San Francisco, CA: 6th Annual Meeting of the Federation-of-Clinical-Immunology-Societies 119, pp. S128-S129.
  • Faaij CMJM, Annels NE, Zuidwijk K, Lankester AC, Revesz T, Bierings M, Egeler RM, van Tol MJD. (2005) 'Possible involvement of CCL28 in the localisation of CCR3+T-cells in intestinal GvHD'. NATURE PUBLISHING GROUP BONE MARROW TRANSPLANTATION, Prague, CZECH REPUBLIC: 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group 35, pp. S134-S134.
  • Annels NE, Faaij CMJM, Lankester AC, Spierings E, Schilham MW, Bowman EP, Bierings M, Revesz T, Egeler RM, Leiden MJDV. (2005) 'Identification Of a skin-homing population of CD4+T cells in patients with skin GvHD'. NATURE PUBLISHING GROUP BONE MARROW TRANSPLANTATION, Prague, CZECH REPUBLIC: 31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group 35, pp. S134-S135.
  • Rickinson AB, Callan MFC, Annels NE. (2000) 'T-cell memory: lessons from Epstein-Barr virus infection in man'. ROYAL SOC LONDON PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES, LONDON, ENGLAND: Synposium on Immunological Memory 355 (1395), pp. 391-400.

Page Owner: na0010
Page Created: Tuesday 3 January 2012 11:23:26 by pr0004
Last Modified: Monday 16 January 2012 14:36:05 by na0010
Expiry Date: Saturday 27 November 2010 15:58:24
Assembly date: Fri Nov 21 22:28:30 GMT 2014
Content ID: 70660
Revision: 2
Community: 1196